Cargando…
Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691861/ https://www.ncbi.nlm.nih.gov/pubmed/30842122 http://dx.doi.org/10.1136/annrheumdis-2018-214261 |
| _version_ | 1783443464692695040 |
|---|---|
| author | Combe, Bernard Balsa, Alejandro Sarzi-Puttini, Piercarlo Tony, Hans-Peter de la Torre, Inmaculada Rogai, Veronica Durand, Frederick Witt, Sarah Zhong, Jinglin Dougados, Maxime |
| author_facet | Combe, Bernard Balsa, Alejandro Sarzi-Puttini, Piercarlo Tony, Hans-Peter de la Torre, Inmaculada Rogai, Veronica Durand, Frederick Witt, Sarah Zhong, Jinglin Dougados, Maxime |
| author_sort | Combe, Bernard |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6691861 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-66918612019-08-26 Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib Combe, Bernard Balsa, Alejandro Sarzi-Puttini, Piercarlo Tony, Hans-Peter de la Torre, Inmaculada Rogai, Veronica Durand, Frederick Witt, Sarah Zhong, Jinglin Dougados, Maxime Ann Rheum Dis Letter BMJ Publishing Group 2019-08 2019-03-06 /pmc/articles/PMC6691861/ /pubmed/30842122 http://dx.doi.org/10.1136/annrheumdis-2018-214261 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
| spellingShingle | Letter Combe, Bernard Balsa, Alejandro Sarzi-Puttini, Piercarlo Tony, Hans-Peter de la Torre, Inmaculada Rogai, Veronica Durand, Frederick Witt, Sarah Zhong, Jinglin Dougados, Maxime Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib |
| title | Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib |
| title_full | Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib |
| title_fullStr | Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib |
| title_full_unstemmed | Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib |
| title_short | Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib |
| title_sort | efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691861/ https://www.ncbi.nlm.nih.gov/pubmed/30842122 http://dx.doi.org/10.1136/annrheumdis-2018-214261 |
| work_keys_str_mv | AT combebernard efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib AT balsaalejandro efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib AT sarziputtinipiercarlo efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib AT tonyhanspeter efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib AT delatorreinmaculada efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib AT rogaiveronica efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib AT durandfrederick efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib AT wittsarah efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib AT zhongjinglin efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib AT dougadosmaxime efficacyandsafetydatabasedonhistoricalorpreexistingconditionsatbaselineforpatientswithactiverheumatoidarthritiswhoweretreatedwithbaricitinib |